Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer 'Moonshot' Recommendations On R&D Have Strong Patient Focus

Executive Summary

Blue ribbon panel has plenty of industry-friendly recommendations on ways to accelerate oncology science, but with the clock ticking down on the Obama Administration, the question is whether the recommendations have any political traction.

You may also be interested in...



Cancer Moonshot To Tackle Hereditary Colon Cancer Screening

One of the recent recommendations for a Cancer Moonshot demonstration program is to implement genetic testing on a wider scale in family members of people with colon cancer-associated genetic mutations. But with greater visibility, how should the testing paradigm change?

FDA's Pazdur Won't Become Oncology Bureaucrat: 'My Presence Will Be Felt'

Richard Pazdur is stepping aside from FDA's Office of Hematology and Oncology Products to head the agency's newly created Oncology Center of Excellence, but he expects to still run twice-weekly group meetings at OHOP.

Cancer “Moonshot” Launch Team Announced: Uncomfortable Ties To Anti-Industry Headlines

The Vice President’s cancer “moonshot” is a great opportunity for biopharma companies to engage in a process that should remind policymakers and the public of the promise of biomedical innovation at a time when the industry’s pricing and financial engineering activities are under scrutiny on Capitol Hill. The selection of the “blue ribbon” panel puts those two images in stark contrast.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel